IRICoR

Client

IRICoR

Year

2016-today

Services

Program assessment, Product assessment, Competitive Landscape Analysis, Stakeholder Analysis, Scientific Due Diligence, Regulatory Strategy, Forecasting, Target Product Profile, Market Assessment, Development Plan, Investor Pitch

Field

Platforms and Therapeutics

Challenge

To provide Business Development advisory, Competitive Landscape Analysis, Scientific Due Diligence, and Market Assessment for a number of projects

“Novateur team was able to help us address a number of critical commercial and regulatory issues facing one of our start-up companies working in the cell therapy and oncology field. Novateur delivered actionable recommendations that allowed us to deliver a clear and complete business plan to potential investors. On a separate mandate we utilized Novateur’s business development experts to advise us on partnerships.”

Steven J. Klein, PhD, MBA
Vice-President, Business Development, IRICoR

image

Quebec-based non-for-profit organization engages Novateur experts for business development and scientific due diligence advisory support

Since 2017, IRICoR has engaged Novateur’s team of experts for a number of mandates. Those included Business Development advisory, Competitive Landscape Analysis, Scientific Due Diligence, and Market Assessment for a number of its projects.  Novateur continues to support IRICoR on a number of projects, including those being spun-off into new companies. 

Learn more about IRICoR

 

Press Release (May 18, 2022): Novateur Ventures Participates in Founding and Financing of Epitopea, a New Cancer Therapeutics Company

"Novateur Ventures, a leading global life sciences advisory firm, announced it has participated in the $13.6M (£10.3M) seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal (UdeM) / IRIC in partnership with IRICoR. This investment will support the further development and application of Epitopea’s ground-breaking approaches to identify shared, aberrantly expressed tumor-specific antigens (TSA), that Epitopea has exclusively licensed from UdeM."

Novateur Newsletter

Subscribe to our newsletter for access to latest updates.

Resource Databases

Access Novateur news as well as FDA and Expert Databases.

Relevant Events

Check out conferences and events we are attending!